erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the . a senior northern ireland civil servant has apologised after hundreds of neurology patients were recalled for further testing. .
following close on aimovig's heels are three other drugs that target cgrp: fremanezumab, galcanezumab, and eptinezumab (which is given by iv). . .